期刊文献+

晚期氧化蛋白产物与慢性肾脏病Ⅴ期非透析患者心血管疾病的关系 被引量:2

Relationship between Advanced Oxidation Protein Products and Cardiovascular Diseases in Nondialysis Patients with Stage Ⅴ Chronic Kidney Disease
下载PDF
导出
摘要 目的:观察慢性肾脏病Ⅴ期(CKDⅤ期)非透析患者血浆晚期氧化蛋白产物(AOPPs)水平,并探讨AOPPs与CKD患者心血管疾病(CVD)的关系。方法:对50例CKDⅤ期非透析患者(CKD组)及31例健康志愿者(对照组)进行血浆AOPPs测定。CKD组同时检测血生化指标,并使用彩色多普勒超声诊断仪检测颈动脉粥样硬化相关指标及左心室肥厚相关指标。分析AOPPs与颈动脉粥样硬化、左心室肥厚及既往CVD病史的关系。结果:CKD组血浆AOPPs水平明显高于对照组(P<0.01)。血浆AOPPs水平与颈总动脉IMT(r=0.593,P<0.01)及LVM(Ir=0.355,P<0.05)呈正相关。多元逐步回归分析,AOPPs是颈总动脉IMT(β=0.574,P<0.01)及LVM(Iβ=0.336,P<0.05)的显著相关因素。既往有CVD史的患者血浆AOPPs水平显著高于既往无CVD的患者(P<0.05)。结论:CKDⅤ期非透析患者普遍存在高AOPPs血症,AOPPs可能参与慢性肾脏病Ⅴ期非透析患者CVD的发生和发展。 Objective:To investigate the relationship between plasma advanced oxidation protein products (AOPPs) and cardiovascular disease (CVD) in nondialysis patients with stage V chronic kidney disease (CKD). Methods:Fifty patients with stage V CKD and 31 healthy controls were enrolled in this study. Plasma levels of AOPPs were tested in both groups. Biochemical indexes were tested in observed group. Color-coded duplex sonography was used to determine the carotid atherosclerosis and left ventricular hypertrophy (LVH) indexes. The correlations between AOPPs and CVD were analyzed. Results:The serum AOPPs level was obviously higher in the observed group than that of control group (P 〈 0.01). Plasma AOPPs level was positively correlated with common carotid artery IMT(r = 0.593 ,P 〈 0.01 )and LVMI(r = 0.355 ,P 〈 0.05). Multiple linear stepwise regression analysis showed that AOPPs were obvious correlation factors to common carotid artery IMT (β=0.574 ,P 〈 0.01) and LVMI (β = 0.336,P 〈 0.05). Those patients who had previous CVD had obviously higher serum AOPPs [(22.29±9.20)vs (16.89±3.40) μmol/L,P 〈 0.05]. Conclusion :The nondialysis patients with stage V CKD had higher AOPPs levels. AOPPs may be involved in the occurrence and progress of CVD in nondialysis patients with stage V CKD.
出处 《天津医药》 CAS 北大核心 2009年第6期449-452,共4页 Tianjin Medical Journal
关键词 蛋白水解产物 慢性病 肾疾病 心血管疾病 回归分析 protein hydrolysates chronic disease kidney diseases cardiovascular diseases regression analysis
  • 相关文献

参考文献12

  • 1Kalantar-Zadek K, Block G, Humphreys MH, et al. A low rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patient[J]. J Am Soc Nephrol, 2004, 15(2): 442-453. 被引量:1
  • 2Witko-Sarsat V, Friedlander M, Nguyen-Khoa, et al. Advanced oxidation protein products as a novel mediator of inflammation and monocyte activation in chronic renal failure [J]. J Immunol, 1998, 161(5):2524-2532. 被引量:1
  • 3Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention [J]. Hypertension, 2003, 42(5): 1050--1065. 被引量:1
  • 4Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al.Advaoced oxidation protein products as a novel marker of oxidative stress in uremia[J].Kidney Int, 1996,49 (5) : 1304-1313. 被引量:1
  • 5Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus[J]. Physiol Res, 2002, 51 (6):597-604. 被引量:1
  • 6Witko-Sarsat V, Gausson V, Descamps-Latscha B. Are advanced oxidation protein products potential toxins [J]? Kidney Int Supple, 2003, (84): S11-14. 被引量:1
  • 7杨小兵,侯凡凡,武强,周华,刘郑荣,杨燕,张训.慢性肾脏病患者晚期氧化蛋白产物血症及其与动脉粥样硬化的关系[J].中华内科杂志,2005,44(5):342-346. 被引量:41
  • 8袁方,刘尚喜,侯凡凡,陈瑗,田建伟,刘志强.晚期氧化蛋白产物导致血管内皮细胞氧化应激损伤[J].解放军医学杂志,2004,29(11):951-954. 被引量:20
  • 9游怀舟,杨海春,丁峰,朱秋毓,林善锬,顾勇.尿毒症患者高级蛋白氧化产物与血管钙化的关系及其机制探讨[J].中华肾脏病杂志,2007,23(4):219-223. 被引量:4
  • 10Heaf JG, Lokkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis[J]. Nephrol Dial Trans- plant, 2002, 17(1):112-117. 被引量:1

二级参考文献44

  • 1[1]Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int, 1996, 49(5):1304 被引量:1
  • 2[2]Witko-Sarsat V, Friedlander M, Nguyen AT et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol,1998, 161(5):2524 被引量:1
  • 3[3]Witko-Sarsat V, Gausson V, Nguyen AT et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int, 2003, 64(1):82 被引量:1
  • 4[4]Kaneda H, Taguchi J, Ogasawara K et al. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis, 2002, 162(1):221 被引量:1
  • 5[5]Drueke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation, 2002, 106(17):2212 被引量:1
  • 6[7]Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods, 1989, 119(2):203 被引量:1
  • 7[8]Carter WO, Narayanan PK, Robinson JP. Intracellular hydrogen peroxide and superoxide anion detection in endothelial cells. J Leukoc Biol, 1994, 55(2):253 被引量:1
  • 8[9]SX, Chen Y, Zhou M et al. Inhibitory effect of ebselen on the oxidation of low density lipoprotein. Redox Report, 1995,1:357 被引量:1
  • 9[10]Jungers P, Massy ZA, Khoa TN et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant, 1997,12(12):2597 被引量:1
  • 10[11]Descamps-Latscha B, Witko-Sarsat V. Oxidative stress in chronic renal failure and hemodialysis. Nephrologie, 2003,24(7):377-379 被引量:1

共引文献58

同被引文献64

  • 1张敏芳,钱家麒,徐筱琪,戴慧莉,吴青伟,倪兆慧.慢性肾衰竭患者血清骨保护素浓度与心脏瓣膜钙化的关系[J].中华肾脏病杂志,2007,23(10):626-630. 被引量:5
  • 2Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiolo- of cardiovascular disease in chronic renal disease-J_ Am J Kidney Dis, 1998, 32(5 Suppl 3): S112 -119. 被引量:1
  • 3Gusbeth - Tatomir P, Covic A. Causes and consequences of increased arterial stiffness in chronic kidney disease patients [ J ]. Kidney Blood Press Res ,2007,30 ( 2 ) : 97 - 107. 被引量:1
  • 4Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging bi- omarkers ibr evaluating cardiovascular risk in the chron- ic kidney disease patient:how do new pieces fit into the uremic puzzle[ J ]. Clin J Am Soc Nephrol, 2008,3 (2) :505 -521. 被引量:1
  • 5Stam F, van Guldener C, Becker A, et al. Endothelial dvsfunction contributes to renal function- associated cardiovascular mortality in a population with mild renal insufficiency: the Hoom study [ J]. Am Soc Nephrol, 2006,17(2) :537 -545. 被引量:1
  • 6Siasos G, Tousoulis D, Michalea S, et al. Biomarkers determining cardiovascular risk in patients with kidney disease[ J]. Curr Med Chem, 2012, 19 ( 16 ) : 2555 - 2571. 被引量:1
  • 7Wald DS, Law M, Morris JK. Homocysteine and cardi- ovascular disease:evidence on causality from a meta - analysis [ J ]. BMJ ,2002,325 ( 7374 ) : 1202. 被引量:1
  • 8Balsam A, E1 Kossi MM, Lord R, et al. Cardiovascular disease on hemodialysis: predictors of atherosclerosis and survival [ J ]. Hemodial Int, 2009, 13 ( 3 ) : 278 - 285. 被引量:1
  • 9Jamison RL, Hartigan P, Kaufman JS, et al. Effect of ho- mocvsteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renaldisease: a randomized controlled trial [J ]. JAMA, 2007,298(10) :1163 - 1170. 被引量:1
  • 10Liu C, Wang Q, Guo H, et al. Plasma S - adenosylhomo- cvsteine is a better biomarker of atherosclerosis than ho- mocvsteine in apolipoprotein E-deficient mice fed high dietary methionine [ J ]. J Nutr, 2008,138 ( 2 ) : 311 -315. 被引量:1

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部